Advertisement
LABD vs LABU
Which ETF would AI Choose? Direxion Daily S&P Biotech Bear 3X ETF (LABD) vs. Direxion Daily S&P Biotech Bull 3X ETF (LABU)
Key Takeaways
- LABD and LABU provide opposing daily leveraged exposure to the same underlying benchmark, the S&P Biotechnology Select Industry Index, making them direct inverses rather than complementary holdings.
- Both ETFs employ synthetic structures using swaps and futures for 3x daily leverage (or inverse), with daily reset mechanisms that amplify compounding effects over multi-day periods.
- Expense ratios stand at approximately 1.07% for LABD and 0.96% for LABU, reflecting the higher costs typical of leveraged products compared to unleveraged sector ETFs.
- These funds target short-term tactical trading within the biotechnology sector rather than long-term buy-and-hold strategies due to volatility decay and path dependency.
- Both maintain concentrated exposure to U.S. biotechnology companies through a modified equal-weighted index, with negligible diversification outside healthcare.
- Liquidity profiles support active trading, though structural risks from leverage and daily rebalancing remain consistent across market cycles.
Introduction
Direxion Daily S&P Biotech Bear 3X ETF (LABD) and Direxion Daily S&P Biotech Bull 3X ETF (LABU) offer investors precise, opposing tools for expressing views on biotechnology sector movements. They do not compete as core holdings but serve as tactical alternatives for those seeking amplified daily exposure to the same equal-weighted index of U.S. biotech firms. In the current environment of sector-specific volatility driven by regulatory developments, clinical trial outcomes, and macroeconomic factors, these leveraged products provide differentiated positioning within a high-beta healthcare niche.
Direxion Daily S&P Biotech Bear 3X ETF (LABD) Overview
Direxion Daily S&P Biotech Bear 3X ETF (LABD) seeks daily investment results, before fees and expenses, of 300% of the inverse (opposite) of the daily performance of the S&P Biotechnology Select Industry Index. The fund uses a synthetic strategy primarily through swap agreements and futures, with daily rebalancing to maintain the -3x target. It holds no direct equity positions in the underlying index constituents. The expense ratio is 1.07%. As a non-diversified, leveraged inverse product focused exclusively on biotechnology, LABD suits short-term tactical strategies rather than extended holding periods.
Direxion Daily S&P Biotech Bull 3X ETF (LABU) Overview
Direxion Daily S&P Biotech Bull 3X ETF (LABU) seeks daily investment results, before fees and expenses, of 300% of the daily performance of the S&P Biotechnology Select Industry Index. Like its counterpart, it achieves leverage synthetically via swaps and futures contracts, resetting exposure daily. The expense ratio is 0.96%. The fund provides concentrated exposure to U.S. biotechnology companies through the modified equal-weighted index, with no meaningful allocation outside the sector. LABU is structured for short-term directional trading aligned with positive biotechnology momentum.
Industry and Thematic Backdrop
The biotechnology sector operates within a dynamic healthcare environment influenced by clinical trial results, U.S. Food and Drug Administration (FDA) approvals, patent expirations, and policy shifts such as drug pricing reforms. Macroeconomic drivers including interest rate expectations and capital availability for research and development (R&D) further shape performance. Regulatory developments around innovation incentives and merger and acquisition (M&A) activity among pharmaceutical firms add layers of volatility. Sector risks encompass binary outcomes from drug development pipelines and sensitivity to broader equity market sentiment.
Performance and Positioning Comparison
In recent market cycles, LABU has exhibited amplified upside capture during biotechnology rallies tied to positive earnings or sector rotation, while LABD has provided corresponding downside protection during periods of sector weakness. Both instruments demonstrate significantly higher volatility than unleveraged biotechnology exposure due to the 3x daily multiplier and compounding effects. Relative positioning favors LABU in environments of sustained positive momentum and LABD during corrective phases, though path dependency limits predictability beyond single trading sessions.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener for advanced filtering capabilities.
Tickeron AI Verdict
Based on structural efficiency, lower expense ratio, and alignment with prevailing sector momentum indicators, Tickeron’s AI would currently assign a higher probabilistic preference to Direxion Daily S&P Biotech Bull 3X ETF (LABU) for tactical exposure, while acknowledging that Direxion Daily S&P Biotech Bear 3X ETF (LABD) offers symmetric utility during periods of sector underperformance. Selection should reflect individual risk tolerance and time horizon.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LABD is a Hold and LABU is a Hold.
Momentum Indicator for LABD turns negative, indicating new downward trend
LABD saw its Momentum Indicator move below the 0 level on October 26, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned negative. In 85 of the 89 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for LABD turned negative on October 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 52 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
LABD moved below its 50-day moving average on October 27, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LABD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
LABD broke above its upper Bollinger Band on October 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 10-day moving average for LABD crossed bullishly above the 50-day moving average on October 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +6.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where LABD advanced for three days, in 249 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
The Aroon Indicator entered an Uptrend today. In 155 of 161 cases where LABD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Momentum Indicator for LABU turns positive, indicating new upward trend
LABU saw its Momentum Indicator move above the 0 level on October 27, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned positive. In 90 of the 93 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for LABU just turned positive on October 21, 2026. Looking at past instances where LABU's MACD turned positive, the stock continued to rise in 48 of 50 cases over the following month. The odds of a continued upward trend are 90%.
Following a +6.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where LABU advanced for three days, in 294 of 311 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
LABU may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LABU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for LABU entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
| LABD | LABU | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 3 days ago 90% | 3 days ago 90% |
| Momentum ODDS (%) | 3 days ago 90% | 3 days ago 90% |
| MACD ODDS (%) | 3 days ago 90% | 3 days ago 90% |
| TrendWeek ODDS (%) | 3 days ago 90% | 3 days ago 90% |
| TrendMonth ODDS (%) | 3 days ago 90% | 3 days ago 90% |
| Advances ODDS (%) | 10 days ago 90% | 4 days ago 90% |
| Declines ODDS (%) | 4 days ago 90% | 10 days ago 90% |
| BollingerBands ODDS (%) | 3 days ago 90% | 3 days ago 90% |
| Aroon ODDS (%) | 3 days ago 90% | 3 days ago 90% |
Advertisement
LABU and
Correlation & Price change
A.I.dvisor indicates that over the last year, LABU has been loosely correlated with RCUS. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if LABU jumps, then RCUS could also see price increases.
| Ticker / NAME | Correlation To LABU | 1D Price Change % | ||
|---|---|---|---|---|
| LABU | 100% | -3.79% | ||
| RCUS - LABU | 57% Loosely correlated | -2.26% | ||
| LYEL - LABU | 57% Loosely correlated | -2.34% | ||
| LGND - LABU | 56% Loosely correlated | +1.71% | ||
| CUE - LABU | 48% Loosely correlated | -2.70% | ||
| AGEN - LABU | 48% Loosely correlated | -3.53% | ||
More | ||||